- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05208060
Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells
A Phase I/II Randomized, Prospective, Double-blind, Placebo-controlled, Single-center Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Bacillus Calmette-Guérin (BCG) has been postulated as a strategy to prevent transmission and reduce the incidence of infectious diseases due to its ability to induce trained immunity. However, it is not recommended to vaccinate with live-attenuated vaccines, such as BCG, to certain vulnerable populations including immunocompromised patients. This issue can be overcome with inactivated preparations that mediate trained immunity such as MV130. The safety of MV130 in pilot studies in patients with immunodeficiency or solid organ recipients, has been highlighted in recent studies.
Based on the principles of trained immunity, it has recently been suggested that this concept can be further exploited in a next generation of anti-infectious vaccines: Trained immunity-based vaccines (TIbV). Thus, these vaccines may confer a broad protection far beyond to the nominal antigens they contain.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Miguel Casanovas Verges, MD, PhD
- Phone Number: 664277223
- Email: mcasanovas@inmunotek.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects that have provided written informed consent.
- Healthy males and females 18 to 65 years, both included, at the time of enrolment.
- Subjects who are able to provide cooperation and comply with dosing regimen.
- Women of childbearing age (from menarche) should submit a urine pregnancy test with a negative result at the time of enrolment in the trial.
Exclusion Criteria:
- Simultaneous participation in another clinical trial.
- Females who are pregnant or breast-feeding, or potential pregnant or breast-feeding females.
- Subjects who are allergic to any of the components included in MV130.
- Subjects with any concomitant disease or treatment that, according to the investigator criteria, may affect the development of this study, such as immunodeficiencies, malignancies involving bone marrow or lymphoid systems, medical treatment affecting the immune system (including corticosteroids, immunosuppressants, biological agents,…), human immunodeficiency virus, - - Subjects who have been vaccinated (flu, pneumococcal or any other vaccine different from COVID-19 vaccine) within 6 months before inclusion, or who have planned to be vaccinated during the clinical trial (excluding the COVID-19 vaccine).
- Subjects who have had an infection that included fever and/or diarrhoea within 3 months before inclusion.
- Subjects under metformin treatment during the last month before inclusion in
Subjects under statins treatment during the last month before inclusion in the clinical trial or during *.
- these drugs interfere with metabolic pathways involved in trained immunity induction
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MV130
Suspension of 6 inactivated whole bacteria concentrates, that contains 90% of Gram positive bacteria (V104 S. pneumoniae 60%, V102 S. aureus 15%, V101 S. epidermidis 15%) and 10% of Gram negative bacteria (V113 K. pneumoniae 4%, V105 M. catarrhalis 3%, V103 H. influenzae 3%), at a concentration of 300 FTU/mL, equivalent to ~ 10^9 bacteria/mL.
|
Treatment administered sublingually
|
Placebo Comparator: Placebo
Sodium chloride 9 mg/mL and water for injection s.q.
f 1 mL.
|
Treatment administered sublingually
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Increase ex vivo in cytokine response
Time Frame: 70 days
|
The primary outcome is the change ex vivo in cytokine response (TNF-alfa, IL-6 and/or IL-1beta) in PBMCs upon secondary restimulation (MV130, lipopolysaccharide [LPS], inactivated Candida albicans, Resiquimod-R848, Poly I:C and/or phytohemagglutinin [PHA]) in MV130 vaccinated subjects compared to placebo group, at days 15, 45 and/or 70, with respect to baseline.
|
70 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in epigenetic markers (miRNA) in purified monocytes from PBMCs in a subgroup of MV130 vaccinated (n=12) versus placebo (n=12), at day 45 with respect to baseline.
Time Frame: 70 days
|
Changes in specific miRNA from total RNA associated to trained immunity (miR155, miR146 and/or miR21, etc.) by real time quantitative polymerase chain reaction (RT-qPCR) measured as expression levels.
|
70 days
|
Changes in epigenetic markers (active chromatin histone marks) in purified monocytes from PBMCs, in a subgroup of MV130 vaccinated (n=12) versus placebo (n=12), at day 45 with respect to baseline, including:
Time Frame: 70 days
|
Changes in active chromatin histone marks (H3K4me3 and/or H3K27me3, among others) by chromatin immunoprecipitation (ChIP) analysis, measured as relative expression.
|
70 days
|
Metabolic changes in purified monocytes from PBMCs, in a subgroup of vaccinated (n=12) versus placebo (n=12), at day 45 with respect to baseline, including:
Time Frame: 70 days
|
Changes in concentration of lactate production by using a colorimetric assay kit. Changes in glucose consumption (concentration), determined by using a glucose assay kit. Changes in mitochondrial activity, measured by using a fluorescence probe kit. |
70 days
|
Changes in percentages of immune populations in peripheral blood
Time Frame: 70 days
|
Changes in percentages of immune populations in peripheral blood including T and B cells, NK cells and subsets of monocytes, in MV130 group compared to placebo at days 15, 45 and/or 70, with respect to baseline.
|
70 days
|
Change in MV130 non-specific response
Time Frame: 70 days
|
Change in MV130 non-specific response (T and B cells from PBMCs) in MV130 treated group compared to placebo including:
|
70 days
|
MV130 specific response
Time Frame: 70 days
|
MV130 specific response (T and B cell responses from PBMCs) in MV130 vaccinated group compared to placebo, including:
|
70 days
|
Changes in baseline oral microbiota composition in MV130 treated group
Time Frame: 70 days
|
Changes in baseline oral microbiota composition in MV130 treated group (days 45 and 70 with respect to baseline) compared to placebo, based o¬n the 16S rRNA sequence phylogeny
|
70 days
|
Rates of adverse events
Time Frame: 70 days
|
The overall rate of adverse events in both groups
|
70 days
|
Classification of the Adverse events
Time Frame: 70 days
|
Classification of the Adverse events during the trial
|
70 days
|
Rates of adverse reactions
Time Frame: 70 days
|
The overall rate of adverse reactions in both groups
|
70 days
|
Classification of the Adverse reactions
Time Frame: 70 days
|
Classification of the Adverse reactions during the trial
|
70 days
|
Percentage by type of adverse events
Time Frame: 70 days
|
Percentage by type of adverse events occurred during the trial
|
70 days
|
Percentage of subject with adverse reactions
Time Frame: 70 days
|
Percentage of subject experiencing adverse reactions during the trial
|
70 days
|
Timing of reaction appearance
Time Frame: 70 days
|
Time from the first administration to appearance of the reaction
|
70 days
|
Classification of the adverse reaction according to the place of appearance
Time Frame: 70 days
|
Classification of the adverse reaction in local or systemic, depending on the place of appearance
|
70 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: ssramon@salud.madrid.org Sánchez-Ramón, MD and PhD, Hospital Clinico San Carlos
Publications and helpful links
General Publications
- Netea MG, Dominguez-Andres J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, Joosten LAB, van der Meer JWM, Mhlanga MM, Mulder WJM, Riksen NP, Schlitzer A, Schultze JL, Stabell Benn C, Sun JC, Xavier RJ, Latz E. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020 Jun;20(6):375-388. doi: 10.1038/s41577-020-0285-6. Epub 2020 Mar 4.
- Cirauqui C, Benito-Villalvilla C, Sanchez-Ramon S, Sirvent S, Diez-Rivero CM, Conejero L, Brandi P, Hernandez-Cillero L, Ochoa JL, Perez-Villamil B, Sancho D, Subiza JL, Palomares O. Human dendritic cells activated with MV130 induce Th1, Th17 and IL-10 responses via RIPK2 and MyD88 signalling pathways. Eur J Immunol. 2018 Jan;48(1):180-193. doi: 10.1002/eji.201747024. Epub 2017 Sep 14.
- Alecsandru D, Valor L, Sanchez-Ramon S, Gil J, Carbone J, Navarro J, Rodriguez J, Rodriguez-Sainz C, Fernandez-Cruz E. Sublingual therapeutic immunization with a polyvalent bacterial preparation in patients with recurrent respiratory infections: immunomodulatory effect on antigen-specific memory CD4+ T cells and impact on clinical outcome. Clin Exp Immunol. 2011 Apr;164(1):100-7. doi: 10.1111/j.1365-2249.2011.04320.x.
- Sanchez-Ramon S, Conejero L, Netea MG, Sancho D, Palomares O, Subiza JL. Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations. Front Immunol. 2018 Dec 17;9:2936. doi: 10.3389/fimmu.2018.02936. eCollection 2018.
- Garcia Gonzalez LA, Arrutia Diez F. Mucosal bacterial immunotherapy with MV130 highly reduces the need of tonsillectomy in adults with recurrent tonsillitis. Hum Vaccin Immunother. 2019;15(9):2150-2153. doi: 10.1080/21645515.2019.1581537. Epub 2019 Apr 17.
- Molero-Abraham M, Sanchez-Trincado JL, Gomez-Perosanz M, Torres-Gomez A, Subiza JL, Lafuente EM, Reche PA. Human Oral Epithelial Cells Impair Bacteria-Mediated Maturation of Dendritic Cells and Render T Cells Unresponsive to Stimulation. Front Immunol. 2019 Jun 28;10:1434. doi: 10.3389/fimmu.2019.01434. eCollection 2019.
- Guevara-Hoyer K, Saz-Leal P, Diez-Rivero CM, Ochoa-Grullon J, Fernandez-Arquero M, Perez de Diego R, Sanchez-Ramon S. Trained Immunity Based-Vaccines as a Prophylactic Strategy in Common Variable Immunodeficiency. A Proof of Concept Study. Biomedicines. 2020 Jul 9;8(7):203. doi: 10.3390/biomedicines8070203.
- Nieto A, Mazon A, Nieto M, Calderon R, Calaforra S, Selva B, Uixera S, Palao MJ, Brandi P, Conejero L, Saz-Leal P, Fernandez-Perez C, Sancho D, Subiza JL, Casanovas M. Bacterial Mucosal Immunotherapy with MV130 Prevents Recurrent Wheezing in Children: A Randomized, Double-Blind, Placebo-controlled Clinical Trial. Am J Respir Crit Care Med. 2021 Aug 15;204(4):462-472. doi: 10.1164/rccm.202003-0520OC.
- Vazquez A, Fernandez-Sevilla LM, Jimenez E, Perez-Cabrera D, Yanez R, Subiza JL, Varas A, Valencia J, Vicente A. Involvement of Mesenchymal Stem Cells in Oral Mucosal Bacterial Immunotherapy. Front Immunol. 2020 Nov 19;11:567391. doi: 10.3389/fimmu.2020.567391. eCollection 2020.
- Del Fresno C, Garcia-Arriaza J, Martinez-Cano S, Heras-Murillo I, Jarit-Cabanillas A, Amores-Iniesta J, Brandi P, Dunphy G, Suay-Corredera C, Pricolo MR, Vicente N, Lopez-Perrote A, Cabezudo S, Gonzalez-Corpas A, Llorca O, Alegre-Cebollada J, Garaigorta U, Gastaminza P, Esteban M, Sancho D. The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity. Front Immunol. 2021 Nov 18;12:748103. doi: 10.3389/fimmu.2021.748103. eCollection 2021.
- Ochoa-Grullon J, Benavente Cuesta C, Gonzalez Fernandez A, Cordero Torres G, Perez Lopez C, Pena Cortijo A, Conejero Hall L, Mateo Morales M, Rodriguez de la Pena A, Diez-Rivero CM, Rodriguez de Frias E, Guevara-Hoyer K, Fernandez-Arquero M, Sanchez-Ramon S. Trained Immunity-Based Vaccine in B Cell Hematological Malignancies With Recurrent Infections: A New Therapeutic Approach. Front Immunol. 2021 Feb 12;11:611566. doi: 10.3389/fimmu.2020.611566. eCollection 2020.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- MV130-SLG-039
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immune Response
-
University of OxfordRecruiting
-
Biosearch S.A.Completed
-
Mayo ClinicCompletedImmune ResponseUnited States
-
National Institute on Aging (NIA)Completed
-
Radboud University Medical CenterCompletedInnate Immune Response | Immune Tolerance
-
Gadjah Mada UniversityCompletedHumoral Immune ResponseIndonesia
-
Radboud University Medical CenterCompletedInnate Immune Response
-
Society for Applied StudiesNorwegian Institute of Public Health; Christian Medical College, Vellore, IndiaCompletedInnate Immune ResponseIndia
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceRecruiting
-
QIAGEN Gaithersburg, IncTerminatedCell-mediated Immune ResponseUnited States
Clinical Trials on MV130
-
Inmunotek S.L.Active, not recruitingChronic Obstructive Pulmonary Disease (COPD)Spain
-
Inmunotek S.L.Withdrawn